C. Galmarini, J. Mackey, and C. Dumontet, Nucleoside analogues and nucleobases in cancer treatment, The Lancet Oncology, vol.3, issue.7, pp.415-424, 2002.
DOI : 10.1016/S1470-2045(02)00788-X

J. Mackey, R. Mani, M. Selner, D. Mowles, J. Young et al., Functional nucleoside transporters are required for gemcitabine influx and manifestation of toxicity in cancer cell lines, Cancer Res, vol.58, pp.4349-4357, 1998.

K. Graham, J. Leithoff, I. Coe, D. Mowles, J. Mackey et al., Differential Transport of Cytosine-Containing Nucleosides by Recombinant Human Concentrative Nucleoside Transporter Protein hCNT1, Nucleosides, Nucleotides and Nucleic Acids, vol.35, issue.1-2, pp.415-434, 2000.
DOI : 10.1016/0005-2736(92)90156-G

D. Bouffard, J. Laliberte, and R. Momparler, Kinetic studies on 2',2'-difluorodeoxycytidine (gemcitabine) with purified human deoxycytidine kinase and cytidine deaminase, Biochemical Pharmacology, vol.45, issue.9, pp.1857-1861, 1993.
DOI : 10.1016/0006-2952(93)90444-2

W. Plunkett, P. Huang, and V. Gandhi, Preclinical characteristics of gemcitabine, Anti-Cancer Drugs, vol.6, issue.Supplement 6, pp.7-13, 1995.
DOI : 10.1097/00001813-199512006-00002

T. Neff and C. Blau, Forced expression of cytidine deaminase confers resistance to cytosine arabinoside and gemcitabine, Exp Hematol, vol.24, pp.1340-1346, 1996.

A. Bergman, G. Giaccone, C. Van-moorsel, R. Mauritz, P. Noordhuis et al., Cross-resistance in the 2???,2???-difluorodeoxycytidine (gemcitabine)-resistant human ovarian cancer cell line AG6000 to standard and investigational drugs, European Journal of Cancer, vol.36, issue.15, pp.1974-1983, 2000.
DOI : 10.1016/S0959-8049(00)00246-X

M. Schirmer, A. Stegmann, F. Geisen, and G. Konwalinka, Lack of crossresistance with gemcitabine and cytarabine in cladribineresistant HL60 cells with elevated 5'-nucleotidase activity

V. Ruiz-van-haperen, G. Veerman, J. Vermorken, and G. Peters, 2???,2???-Difluoro-deoxycytidine (gemcitabine) incorporation into RNA and DNA of tumour cell lines, Biochemical Pharmacology, vol.46, issue.4, pp.762-766, 1993.
DOI : 10.1016/0006-2952(93)90566-F

V. Heinemann, Y. Xu, S. Chubb, A. Sen, L. Hertel et al., Inhibition of ribonucleotide reduction in CCRF-CEM cells by 2',2'-difluorodeoxycytidine, Mol Pharmacol, vol.38, pp.567-572, 1990.

W. Plunkett, P. Huang, Y. Xu, V. Heinemann, R. Grunewald et al., Gemcitabine: metabolism, mechanisms of action, and selfpotentiation, Semin Oncol, vol.22, pp.3-10, 1995.

C. Baker, J. Banzon, J. Bollinger, J. Stubbe, V. Samano et al., 2'-Deoxy-2'-methylenecytidine and 2'-deoxy-2',2'-difluorocytidine 5'-diphosphates: potent mechanism-based inhibitors of ribonucleotide reductase, Journal of Medicinal Chemistry, vol.34, issue.6, pp.1879-1884, 1991.
DOI : 10.1021/jm00110a019

P. Huang, S. Chubb, L. Hertel, G. Grindey, and W. Plunkett, Action of 2',2'-difluorodeoxycytidine on DNA synthesis, Cancer Res, vol.51, pp.6110-6117, 1991.

V. Heinemann, L. Schulz, R. Issels, and W. Plunkett, Gemcitabine: a modulator of intracellular nucleotide and deoxynucleotide metabolism, Semin Oncol, vol.22, pp.11-18, 1995.

C. Galmarini, J. Mackey, and C. Dumontet, Nucleoside analogues: mechanisms of drug resistance and reversal strategies, Leukemia, vol.15, issue.6, pp.875-890, 2001.
DOI : 10.1038/sj.leu.2402114

L. Jordheim, C. Galmarini, and C. Dumontet, Drug Resistance to Cytotoxic Nucleoside Analogues, Current Drug Targets, vol.4, issue.6, pp.443-460, 2003.
DOI : 10.2174/1389450033490957

A. Bergman, H. Pinedo, and G. Peters, Determinants of resistance to 2???,2???-difluorodeoxycytidine (gemcitabine), Drug Resistance Updates, vol.5, issue.1, pp.19-33, 2002.
DOI : 10.1016/S1368-7646(02)00002-X

V. Ruiz-van-haperen, G. Veerman, S. Eriksson, E. Boven, A. Stegmann et al., Development and molecular characterization of a 2',2'-difluorodeox- ycytidine-resistant variant of the human ovarian carcinoma cell line A2780, Cancer Res, vol.54, pp.4138-4143, 1994.

C. Dumontet, K. Fabianowska-majewska, D. Mantincic, C. Bauchu, E. Tigaud et al., Common resistance mechanisms to deoxynucleoside analogues in variants of the human erythroleukaemic line K562, British Journal of Haematology, vol.71, issue.1, pp.78-85, 1999.
DOI : 10.1016/S0959-8049(96)00347-4

C. Van-der-wilt, J. Kroep, A. Bergman, W. Loves, E. Alvarez et al., The Role of Deoxycytidine Kinase in Gemcitabine Cytotoxicity, Adv Exp Med Biol, vol.486, pp.287-290, 2000.
DOI : 10.1007/0-306-46843-3_56

Y. Goan, B. Zhou, E. Hu, S. Mi, and Y. Y. , Overexpression of ribonucleotide reductase as a mechanism of resistance to 2,2-dif- luorodeoxycytidine in the human KB cancer cell line, Cancer Res, vol.59, pp.4204-4207, 1999.

C. Galmarini, M. Clarke, N. Falette, A. Puisieux, J. Mackey et al., Expression of a non-functional p53 affects the sensitivity of cancer cells to gemcitabine, International Journal of Cancer, vol.10, issue.4, pp.439-445, 2002.
DOI : 10.1002/ijc.1628

C. Galmarini, M. Clarke, C. Santos, L. Jordheim, C. Perigaud et al., Sensitization of ara-C-resistant lymphoma cells by a pronucleotide analogue, International Journal of Cancer, vol.8, issue.1, pp.149-154, 2003.
DOI : 10.1002/ijc.11339

A. Bergman, H. Pinedo, R. Van-haperen, V. Veerman, G. Kuiper et al., Cross-Resistance of the Gemcitabine Resistant Human Ovarian Cancer Cell Line AG6000 to Standard and Investigational Drugs, Adv Exp Med Biol, vol.431, pp.587-590, 1998.
DOI : 10.1007/978-1-4615-5381-6_113

A. Bergman, H. Pinedo, A. Jongsma, M. Brouwer, R. Van-haperen et al., Decreased resistance to gemcitabine (2???,2???-difluorodeoxycitidine) of cytosine arabinoside-resistant myeloblastic murine and rat leukemia cell lines: role of altered activity and substrate specificity of deoxycytidine kinase, Biochemical Pharmacology, vol.57, issue.4, pp.397-406, 1999.
DOI : 10.1016/S0006-2952(98)00318-9

A. Blackstock, H. Lightfoot, L. Case, J. Tepper, S. Mukherji et al., Tumor uptake and elimination of 2',2'-difluoro-2'-deoxycytidine (gemcitabine) after deoxycytidine kinase gene transfer: correlation with in vivo tumor response, Clin Cancer Res, vol.7, pp.3263-3268, 2001.

T. Obata, Y. Endo, M. Tanaka, H. Uchida, A. Matsuda et al., Deletion Mutants of Human Deoxycytidine Kinase mRNA in Cells Resistant to Antitumor Cytosine Nucleosides, Japanese Journal of Cancer Research, vol.88, issue.7, pp.793-798, 2001.
DOI : 10.1111/j.1349-7006.2001.tb01163.x

M. Veuger, M. Honders, J. Landegent, R. Willemze, and R. Barge, High incidence of alternatively spliced forms of deoxycytidine kinase in patients with resistant acute myeloid leukemia, Blood, vol.96, pp.1517-1524, 2000.

J. Owens, D. Shewach, B. Ullman, and B. Mitchell, Resistance to 1- beta-D-arabinofuranosylcytosine in human T-lymphoblasts mediated by mutations within the deoxycytidine kinase gene, Cancer Res, vol.52, pp.2389-2393, 1992.

H. Gourdeau, M. Clarke, F. Ouellet, D. Mowles, M. Selner et al., Mechanisms of uptake and resistance to troxacitabine, a novel deoxycytidine nucleoside analogue, in human leukemic and solid tumor cell lines, Cancer Res, vol.61, pp.7217-7224, 2001.

J. Stubbe and W. Van-der-donk, Ribonucleotide reductases: radical enzymes with suicidal tendencies, Chemistry & Biology, vol.2, issue.12, pp.793-801, 1995.
DOI : 10.1016/1074-5521(95)90084-5

C. Mazzon, C. Rampazzo, M. Scaini, L. Gallinaro, A. Karlsson et al., Cytosolic and mitochondrial deoxyribonucleotidases: activity with substrate analogs, inhibitors and implications for therapy, Biochemical Pharmacology, vol.66, issue.3, pp.471-479, 2003.
DOI : 10.1016/S0006-2952(03)00290-9

J. Reed, Bcl-2 and the regulation of programmed cell death, The Journal of Cell Biology, vol.124, issue.1, pp.1-6, 1994.
DOI : 10.1083/jcb.124.1.1

Y. Hsu, K. Wolter, and R. Youle, Cytosol-to-membrane redistribution of Bax and Bcl-XL during apoptosis, Proceedings of the National Academy of Sciences, vol.92, issue.10, pp.3668-3672, 1997.
DOI : 10.1073/pnas.92.10.4507

O. Connor, L. Strasser, A. , O. Reilly, L. Hausmann et al., Bim: a novel member of the Bcl-2 family that promotes apoptosis, The EMBO Journal, vol.17, issue.2, pp.384-395, 1998.
DOI : 10.1093/emboj/17.2.384

Y. Gazitt, M. Rothenberg, S. Hilsenbeck, V. Fey, C. Thomas et al., Bcl-2 overexpression is associated with resistance to paclitaxel, but not gemcitabine, multiple myeloma cells

Z. Csapo, M. Sasvari-szekely, T. Spasokoukotskaja, I. Talianidis, S. Eriksson et al., Activation of deoxycytidine kinase by inhibition of DNA synthesis in human lymphocytes11Abbreviations: dCK, deoxycytidine kinase; dTK, thymidine kinase; CdA, 2-chloro-2???-deoxyadenosine; araC, 1-??-D-arabinofuranosylcytosine; 3HdC, 2???-deoxy-[5-3H] cytidine; 3HdT, 2???-deoxy-[5-methyl-3H] thymidine; HL 60, human promyelocytic cell line; AML, acute myeloid leukaemia; PBMC, peripherial blood mononuclear cell; APC, aphidicolin; and DEAE, diethylaminoethyl., Biochemical Pharmacology, vol.61, issue.2, pp.191-197, 2001.
DOI : 10.1016/S0006-2952(00)00534-7

Z. Csapo, G. Keszler, G. Safrany, T. Spasokoukotskaja, I. Talianidis et al., Activation of deoxycytidine kinase by gamma-irradiation and inactivation by hyperosmotic shock in human lymphocytes, Biochemical Pharmacology, vol.65, issue.12, pp.2031-2039, 2003.
DOI : 10.1016/S0006-2952(03)00182-5

M. Sasvari-szekely, T. Spasokoukotskaja, M. Szoke, Z. Csapo, A. Turi et al., Activation of deoxycytidine kinase during inhibition of DNA synthesis by 2-chloro-2???-deoxyadenosine (cladribine) in human lymphocytes, Biochemical Pharmacology, vol.56, issue.9, pp.1175-1179, 1998.
DOI : 10.1016/S0006-2952(98)00108-7

T. Spasokoukotskaja, M. Sasvari-szekely, G. Keszler, F. Albertioni, S. Eriksson et al., Treatment of normal and malignant cells with nucleoside analogues and etoposide enhances deoxycytidine kinase activity, European Journal of Cancer, vol.35, issue.13, pp.1862-1867, 1999.
DOI : 10.1016/S0959-8049(99)00223-3

D. Egron, C. Perigaud, G. Gosselin, A. Aubertin, and J. Imbach, SYNTHESIS AND STUDY OF A NEW SERIES OF PHOSPHORAMIDATE DERIVATIVES AS MONONUCLEOTIDE PRODRUGS, Nucleosides, Nucleotides and Nucleic Acids, vol.38, issue.4-7, pp.751-754, 2001.
DOI : 10.1081/NCN-100002422

R. Bazzanini, S. Manfredini, E. Durini, B. Groschel, J. Cinatl et al., -Acyl-2-thioethyl (SATE) Biolabile Phosphate Protecting Group: Synthesis and Biological Evaluation, Nucleosides and Nucleotides, vol.18, issue.4-5, pp.971-972, 1999.
DOI : 10.1021/jm00020a007
URL : https://hal.archives-ouvertes.fr/hal-00017076

M. Beckwith, W. Urba, and D. Longo, Growth Inhibition of Human Lymphoma Cell Lines by the Marine Products, Dolastatins 10 and 15, JNCI Journal of the National Cancer Institute, vol.85, issue.6, pp.483-488, 1993.
DOI : 10.1093/jnci/85.6.483

H. Boleti, I. Coe, S. Baldwin, J. Young, and C. Cass, Molecular identification of the equilibrative NBMPR-sensitive (es) nucleoside transporter and demonstration of an equilibrative NBMPR-insensitive (ei) transport activity in human erythroleukemia (K562) cells, Neuropharmacology, vol.36, issue.9, pp.1167-1179, 1997.
DOI : 10.1016/S0028-3908(97)00136-6

V. Gandhi, L. Danhauser, and W. Plunkett, Separation of 1-beta-D-ara- binofuranosylcytosine 5'-triphosphate and 9-beta-D-arabino- furanosyl-2-fluoroadenine 5'-triphosphate in human leukemia cells by high-performance liquid chromatography

D. Lahiri, S. Bye, J. I. Nurnberger, . Jr, M. Hodes et al., A non-organic and non-enzymatic extraction method gives higher yields of genomic DNA from whole-blood samples than do nine other methods tested, Journal of Biochemical and Biophysical Methods, vol.25, issue.4, pp.193-205, 1992.
DOI : 10.1016/0165-022X(92)90014-2